Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Saved in:
| Title: | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. |
|---|---|
| Authors: | Capdevila J; Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain., Krajewska J; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Hernando J; Vall d'Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain., Robinson B; Department of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Vaisman F; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Hoff AO; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Hitre E; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Williamson D; Department of Biostatistics, Exelixis, Inc., Alameda, California, USA., Levytskyy R; Department of Medical Affairs, Exelixis, Inc., Alameda, California, USA., Oliver J; Department of Clinical Development, Exelixis, Inc., Alameda, California, USA., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Brose MS; Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. |
| Source: | Thyroid : official journal of the American Thyroid Association [Thyroid] 2024 Mar; Vol. 34 (3), pp. 347-359. Date of Electronic Publication: 2024 Jan 23. |
| Publication Type: | Randomized Controlled Trial; Journal Article |
| Journal Info: | Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1557-9077 |
|---|---|
| DOI: | 10.1089/thy.2023.0463 |
